TNF and triple-A syndrome: AAAs develop in approximately 13% of patients with rheumatoid arthritis, spondyloarthritis, or inflammatory bowel disease who are treated with TNF inhibitors, substantially reducing the clinical response, while concomitant immunosuppressive therapy markedly lowers AAA formation [36].